{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

An observational survey to evaluate management pattern of Hypersensitive Pneumonitis and the role of anti-fibrotics in Interstitial lung diseases.

Survey Questionnaire
  1. Approximately, how many patients of Interstitial lung diseases (ILD) do you see in your practice every month? *

  2. Approximately, how many patients are newly diagnosed with Interstitial lung diseases (ILD) in your practice every month? *

  3. Approximately, what is the percentage distribution of various ILD observed in your practice? (Answer in percentages) *

    4. Socoidosis-related

    %

    Connective Tissue ILD

    %

    Hypersensitivity Pneumonitis

    %

    Idiopathic Pulmonary fibrosis

    %
    %
  4. Which is the most common age group when patients are diagnosed with ILD according to the type of ILD, as observed in your practice? (Tick all which are applicable) *
    5. ≤18 yrs 18-30 yrs 31-45 yrs 46-60 yrs >60 yrs

    Idiopathic pulmonary fibrosis (IPF)

    Sarcoidosis

    Connective tissue disease (CTD)- related ilds

    Hypersensitivity pneumonitis

  5. Which are the common presenting symptoms among patients with Interstitial lung disease, as observed in your practice? (Tick all applicable) *

  6. What were the common co-morbidities in ILD patients. Kindly specify % relative % observed in your practice. *

    7. Asthma

    %

    CVD

    %

    GERD

    %

    COPD

    %

    Hypertension

    %
    Mention if any other
    %
    %
  7. Approximately, how many patients newly diagnosed with Interstitial lung diseases (ILD) have a history of smoking, as observed in your practice? *

  8. Approximately, how many patients newly diagnosed with Interstitial lung disease (ILD) have a history of exposure to molds/allergens in observed in your practice? *

  9. What are the diagnostic tests in your practice ? (Tick whatever is applicable) *

  10. Describe the salient features of the HRCT pattern of various types of ILDs *
    11. Idiopathic pulmonary fibrosis (IPF)
    Sarcoidosis
    Connective tissue disease (CTD)- related ILDs
    Hypersensitivity pneumonitis
  11. What are the criteria for progression you consider in your practice? Kindly enumerate the ones you use to evaluate progression in your practice. *
  12. What is the percentage of ILDs showing progression in your practice? *

  13. What percentage of HP patients show progression? *

  14. What are the common domestic/environmental factors that may be the probable cause of HP? *

  15. In your practice, which pattern of HRCT is commonly seen in Fibrotic HP? *

  16. What are the drug/drugs used to treat HP (Tick all the relevant options) *

  17. If Nintedanib is prescribed, what is/are the factors determining the use of the drug in fibrotic HP?

  18. If Perfenidone is prescribed, what is/are the factors determining the use of the drug in fibrotic HP?

  19. Do you agree that dosing and frequency is an advantages of Nintedanib over Pirfenidone? *

  20. Do you use a combination of Nintedanib and Perfenidone in your practice? *

  21. What is the frequency of follow-upin HP patients? *